The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Advances in molecular targeted therapies for pancreatic cancer
Salwan Al Mutar, MD, UT Southwestern Medical Center, Dallas, TX, gives an overview of current research on targeted therapies for pancreatic cancer. Trials are underway assessing KRAS inhibitors, including pan-KRAS and KRAS G12C inhibitors, as well as agents targeting claudin 18.2 and MTAP loss. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
